alopecia areata

Nektar Therapeutics faces securities class action lawsuit alleging REZOLVE-AA trial enrolled four ineligible patients, masking disappointing efficacy results.

Nektar Therapeutics faces securities fraud lawsuit over failed alopecia trial and alleged protocol disclosure violations. Stock fell 7.8% on December 16, 2025.

Pomerantz LLP filed class action against $NKTR over REZOLVE-AA trial failure. Stock dropped 7.77% after December disclosure of ineligible patient enrollment issues.

Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.

Pomerantz LLP sues Nektar Therapeutics for alleged securities fraud over failed clinical trial enrollment; stock falls 7.77%.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.